Abstract: The present invention relates to non-human transgenic animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia. In a preferred embodiment of the present invention, the transgenic animals exhibit a rapid induction of acute leukemia. The present invention offers the advantage of providing, for the first time, a non-human transgenic animal model system which carries the BCR/ABL gene fusion characteristic of the Philadelphia chromosome and which develops leukemia in a manner directly analogous to the clinical progression of chronic myelogenous leukemia (CML) and/or acute lymphoblastic leukemia (ALL) in humans. This model system for human leukemia may be valuable in obtaining a better understanding of CML and ALL and in developing effective therapeutic regimens.

Abstract: The present invention relates to non-human transgenic animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia. In a preferred embodiment of the present invention, the transgenic animals exhibit a rapid induction of acute leukemia.The present invention offers the advantage of providing, for the first time, a non-human transgenic animal model system which carries the BCR/ABL gene fusion characteristic of the Philadelphia chromosome and which develops leukemia in a manner directly analogous to the clinical progression of chronic myelogenous leukemia (CML) and/or acute lymphoblastic leukemia (ALL) in humans. This model system for human leukemia may be valuable in obtaining a better understanding of CML and ALL and in developing effective therapeutic regimens.

Abstract: The present invention relates to nucleic aid molecules which comprise subfragments of ABR gene sequence. In particular embodiments, the nucleic acid molecules of the invention comprise portions of nucleic acid sequence contained in plasmids pVNTR-A or pVNTR-B. The invention is based, in part, on the discovery that a Taq-1 fragment of pVNTR-B, an EcoRI/HindIII fragment of pVNTR-A and, in preferred embodiments, a combination of these two fragments may be used to demonstrate restriction fragment length polymorphisms in the DNA of human subjects. Such restriction fragment length polymorphisms may provide a "genetic fingerprint" which may be used to identify individual persons or to provide evidence of a filial relationship in paternity cases. The nucleic acid sequences of the invention offer the advantage of producing an easily readable pattern in restriction fragment polymorphism analysis.

Abstract: A single-stranded deoxyribonucleic acid molecule having a length of less than about 25 kb comprises at least three distinct nucleotide sequences which are the sites for incorporation into a chromosome of a deoxyribonucleic acid molecule encoding a deleterious gene. Deoxyribonucleic acid probes have been prepared from such molecules and are useful as hybridization probes for detecting chromosomal deoxyribonucleic acid which has a deoxyribonucleic acid molecule encoding a deleterious gene, i.e. oncogene, incorporated therein.A single-stranded deoxyribonucleic acid molecule derived from human chromosome 22 which is about 5.8 kb in length contains sites for incorporation of a deoxyribonucleic acid molecule encoding the oncogene c-abl derived from human chromosome 9. Deoxyribonucleic acid probes have been prepared from this molecule and used to detect the abnormal Philadelphia chromosome and chronic myelocytic leukemia.